Significant Weight Loss Achieved
Eli Lilly’s phase 3 clinical trial for retatrutide has highlighted promising results in weight reduction. The trial results, published in the National Library of Medicine on September 29, demonstrate growing interest in next-generation obesity treatments beyond current GLP-1 therapies like Wegovy and Ozempic.
Retatrutide’s Mechanism
Unlike Wegovy and Ozempic, which target the hormone GLP-1, retatrutide engages three hormone receptors: GLP-1, GIP, and glucagon. The interaction with glucagon potentially boosts energy expenditure and fat burning, leading to substantial weight loss as evidenced in trials.
The trial involved injectable retatrutide and explored various dosages, similar to existing GLP-1 medications, which are available in injectable and pill forms.
Trial Insights and Statistics
The study comprised 2,339 adults with obesity, excluding diabetes patients, over 18 months. Participants were randomly assigned doses of retatrutide at 4, 9, 12 milligrams, or given a placebo. The observed weight loss varied according to dosage: 17.6% reduction for 4 milligrams, 23.7% for 9 milligrams, and 25% for 12 milligrams. The placebo group saw only a 3.9% reduction.
Participants with knee osteoarthritis and sleep apnea reported improvement, indicating wider benefits of retatrutide.
Potential Market Competition
Despite retatrutide’s promising results, Novo Nordisk, manufacturer of Ozempic, is pursuing competitive solutions to rival Eli Lilly’s innovation.
Regulatory Status and Concerns
Retatrutide is yet to receive FDA approval. Eli Lilly intends to seek regulatory sanction post-positive trial outcomes, but no approval date is provided. The drug remains available solely through Lilly’s clinical trials.
Alarmingly, CBS News revealed instances of retatrutide access through unauthorized channels. Eli Lilly warns against these products found online and in stores due to unidentified ingredients and potential health hazards.
Dr. Brian Wojeck cautioned against off-trial use of retatrutide due to the risks of compounded agents, citing the need for regulated, tested solutions.
Safety Concerns
There are reports of two fatalities linked to black market variants of retatrutide, with incidents of cardiac arrest and online purchase under questionable advice. These deaths were unrelated to Eli Lilly’s trial, underscoring the dangers of unregulated substances.
